Panobinostat’s Questionable Magnitude Of Benefit Can’t Outweigh Toxicities, Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis shouldn’t give up on drug for relapsed multiple myeloma, FDA’s Oncologic Drugs Advisory Committee says, even as panel votes against approval based on progression-free survival data.
You may also be interested in...
Will Aducanumab Join List Of Drugs Approved By US FDA Over Advisory Committee Opposition?
A look at drugs the agency approved despite an advisory committee vote not to do so and how they compare to Biogen’s Alzheimer’s disease drug aducanumab.
As Aducanumab’s US FDA Review Progressed, Support Grew For Accelerated Approval
Use of expedited pathway for Biogen's Alzheimer's drug was discussed at a center director briefing in late April, where it garnered backing from several senior CDER officials, as well as CBER director Peter Marks and OCE director Richard Pazdur.
Pink Sheet Podcast: Adcoms Too Emotional, Pushing Gene Therapy Science, Congress Gets UFA Update
Pink Sheet reporter and editors discuss whether emotion could be removed from US FDA advisory committees, adverse events and advancing science in gene therapy development, and Capitol Hill’s interest in the ongoing user fee negotiations.